Trovagene

TROV NASDAQ
2.120
-0.030
-1.40%
After Hours: 2.140 +0.02 +0.94% 16:41 07/15 EDT
Open
2.210
Prev Close
2.150
High
2.210
Low
2.100
Volume
61.78K
Avg Vol (3M)
247.05K
52 Week High
9.65
52 Week Low
2.140
% Turnover
1.18%
Market Cap
11.08M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Trovagene TROV stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.
MORE >

Recently

Name
Price
%Change